Andrew Callos
Fortuna: 4 M $ al 31/05/2026
Fortuna: 4 M $ al 31/05/2026
Andrew M.
Callos is Chief Commercial Officer & Executive VP at Cytokinetics, Inc. since 2021.
Formerly, Mr. Callos was Vice President-US Cardiology & Metabolic Marketing at Pfizer Inc. and Assistant Vice President-Marketing at Wyeth Pharmaceuticals, Inc. Mr. Callos completed undergraduate education at Drexel University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/06/2026 | 58.555 ( 0,05 % ) | 4 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CYTOKINETICS, INCORPORATED | Corporate Officer/Principal | 01/03/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
| PFIZER INC. | Corporate Officer/Principal | - |
Wyeth Pharmaceuticals, Inc.
Wyeth Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Ventas & Marketing | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Cytokinetics, Inc.
Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products | Health Technology |
Drexel University
Drexel University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wyeth Pharmaceuticals, Inc.
Wyeth Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.